.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Queensland Health
QuintilesIMS
Johnson and Johnson
US Army
Farmers Insurance
Healthtrust
Chubb
Medtronic

Generated: December 18, 2017

DrugPatentWatch Database Preview

DURANEST Drug Profile

« Back to Dashboard

When do Duranest patents expire, and when can generic versions of Duranest launch?

Duranest is a drug marketed by Astrazeneca and Dentsply Pharm and is included in two NDAs.

The generic ingredient in DURANEST is etidocaine hydrochloride. Additional details are available on the etidocaine hydrochloride profile page.
Drug patent expirations by year for DURANEST

Medical Subject Heading (MeSH) Categories for DURANEST

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
AstrazenecaDURANESTepinephrine; etidocaine hydrochlorideINJECTABLE;INJECTION017751-004Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-003Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
AstrazenecaDURANESTepinephrine bitartrate; etidocaine hydrochlorideINJECTABLE;INJECTION017751-006Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
AstrazenecaDURANESTepinephrine bitartrate; etidocaine hydrochlorideINJECTABLE;INJECTION017751-007Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Dentsply PharmDURANESTepinephrine bitartrate; etidocaine hydrochlorideINJECTABLE;INJECTION021384-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-005Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DURANEST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTepinephrine bitartrate; etidocaine hydrochlorideINJECTABLE;INJECTION017751-007Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTepinephrine; etidocaine hydrochlorideINJECTABLE;INJECTION017751-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTepinephrine bitartrate; etidocaine hydrochlorideINJECTABLE;INJECTION017751-007Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTepinephrine bitartrate; etidocaine hydrochlorideINJECTABLE;INJECTION017751-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
AstrazenecaDURANESTetidocaine hydrochlorideINJECTABLE;INJECTION017751-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Farmers Insurance
Chubb
UBS
Cipla
Daiichi Sankyo
Fuji
AstraZeneca
Julphar
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot